老年头颈癌放化疗患者新型预后评分的开发与验证
本研究基于284例≥65岁接受根治性放化疗的头颈鳞癌患者开发预后评分,并在217例外部队列中验证。Karnofsky功能状态、Charlson合并症指数和基线C反应蛋白被纳入评分,将患者分为3个生存组,中位总生存分别为107、28和6个月(p<0.001)。外部验证同样显示显著分层(p=0.005),并基于501例聚合数据构建了预测2年和4年总生存的列线图。
要点
- 基于KPS、Charlson合并症指数和基线CRP构建的评分可将老年头颈鳞癌放化疗患者分为3个显著不同的生存组。
- 开发队列中3组中位OS分别为107、28和6个月(p<0.001),外部验证中同样显著分层(p=0.005)。
- 基于501例聚合数据构建的列线图可预测2年和4年总生存,可能辅助该脆弱人群的决策。
核心结论
- 提出并验证了一种基于易获取临床数据的新型预后评分,可对接受放化疗的老年头颈鳞癌患者进行预后分层。
- 基于聚合数据构建的列线图可预测2年和4年总生存,可能有助于该脆弱人群的决策。
研究设计与样本
- 开发队列纳入284例≥65岁接受根治性放化疗的头颈鳞癌患者,基于多变量Cox回归中p<0.1的显著参数beta回归系数构建预测总生存的评分。
- 外部队列纳入217例接受放化疗的老年头颈鳞癌患者进行验证,并使用聚合数据(n=501)开发预测2年和4年总生存的列线图。
主要发现
- 多变量分析中,Karnofsky功能状态(HR=2.654;p<0.001)、Charlson合并症指数(HR=2.598;p<0.001)和基线C反应蛋白水平(HR=1.634;p=0.068)为总生存的预后因素。
- 基于beta回归系数创建的评分纳入功能状态降低、合并症负担增加和CRP水平升高,形成3个 distinct 生存组,中位总生存分别为107、28和6个月(p<0.001)。
- 外部验证队列中,该评分同样显著区分预后良好(中位OS=130个月)、中等(29个月)和不良(9个月)三组(p=0.005)。
关键数值与推荐
- 多变量Cox回归以p<0.1为纳入标准。
- 开发队列3组中位OS分别为107、28和6个月(p<0.001)。
- 外部验证队列3组中位OS分别为130、29和9个月(p=0.005)。
临床怎么用
- 该评分基于KPS、Charlson合并症指数和基线CRP等易获取临床数据,可用于老年头颈鳞癌放化疗患者的预后分层。
- 衍生的列线图可预测2年和4年总生存,可能辅助该脆弱人群的临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To establish a clinically feasible prognostic score and nomogram based on easily accessible clinical data that will aid decision-making in elderly head-and-neck squamous cell carcinoma (HNSCC) patients undergoing (chemo)radiotherapy. MATERIAL AND METHODS: 284 elderly HNSCC patients (≥65 years) undergoing curative (chemo)radiotherapy were included for the development of a score predicting overall survival (OS) based on the beta regression coefficients from significant parameters in a multivariate Cox regression analysis with p < 0.1 as inclusion criterion. A second, external cohort of 217 elderly HNSCC patients receiving (chemo)radiotherapy was used for validation. Using the aggregated data (n = 501), a nomogram was developed to predict 2- and 4-year OS. RESULTS: Karnofsky Performance Status (HR = 2.654; p < 0.001), Charlson Comorbidity Index (HR = 2.598; p < 0.001) and baseline C-reactive protein (CRP) level (HR = 1.634; p = 0.068) were prognostic for OS in the multivariate analysis. An OS score based on beta regression coefficients was created, in which reduced performance status, increased comorbidity burden and increased CRP levels were included, leading to 3 distinct survival groups. The median OS for the 3 groups amounted to 107, 28 and 6 months, respectively (p < 0.001). The developed score was able to significantly differentiate between a favorable (median OS = 130 months), intermediate (29 months) and unfavorable prognosis (9 months) also in the external validation cohort (p = 0.005). CONCLUSION: We propose a novel, validated prognostic score based on easily accessible clinical data allowing stratification between prognostic groups of elderly HNSCC patients receiving (chemo)radiotherapy. The derived nomogram for the prediction of 2-year and 4-year OS may aid decision-making for this vulnerable population.
引用
- Rühle A, Stromberger C, Haehl E, et al. Development and validation of a novel prognostic score for elderly head-and-neck cancer patients undergoing radiotherapy or chemoradiation. Radiother Oncol. 2020. PMID: 33245947. doi:10.1016/j.radonc.2020.11.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。